Novo Nordisk Tells Sens. Ozempic Costs Are Linked To PBMs

By Dani Kass · September 24, 2024, 7:58 PM EDT

Novo Nordisk's CEO argued Tuesday that the high prices of the company's diabetes and weight loss drugs Ozempic and Wegovy primarily stem from the actions of pharmacy benefit managers, earning support...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login